Black Hawk Acquisition CORP

Black Hawk Acquisition Corporation has deposited $150,000 to extend its deadline for consummating an initial business combination by one month.

Black Hawk Acquisition Corporation received a notice from Nasdaq regarding non-compliance with the $50 million market value of listed securities requirement.

Vesicor Therapeutics, a proposed de-SPAC target for Black Hawk Acquisition Corp., has appointed Dr. Michael Tolentino, a seasoned biotech leader, as its new Chief Executive Officer.

Black Hawk Acquisition Corporation has secured a convertible promissory note of up to $300,000 from its sponsor, Black Hawk Management LLC, for working capital.

Black Hawk Acquisition Corporation's proposed business combination target, Vesicor Therapeutics, Inc., announced the appointment of Mitchell Creem as Chief Financial Officer and Frederick Woodruff Field as an independent director.

Black Hawk Acquisition Corporation has extended the deadline to complete its initial business combination by one month to October 22, 2025, following a $150,000 trust account deposit.

Black Hawk Acquisition Corporation files its Q2 2026 10-Q, detailing its ongoing business combination efforts with Vesicor Therapeutics and addressing Nasdaq listing concerns.

Black Hawk Acquisition Corporation has entered a definitive agreement to merge with biotech firm Vesicor Therapeutics, valuing it at $70 million, but faces significant shareholder redemptions and going concern doubts.

Black Hawk Acquisition Corporation, a SPAC, announced its second-quarter 2025 financial results, highlighted by increased net income and progress on its proposed business combination with Vesicor Therapeutics, Inc., while simultaneously disclosing substantial doubt about its ability to continue as a going concern and seeking an extension for its business combination deadline.

Black Hawk Acquisition Corporation reports a net income of $658,379 for the quarter ended February 28, 2025, driven by interest income from investments held in trust.

Black Hawk Acquisition Corporation reported a net income of $883,767 for the third quarter of 2024, primarily driven by interest income from its trust account.

Black Hawk Acquisition Corporation reported a net income of $280,235 for the six months ended May 31, 2024, primarily driven by interest income from its trust account.

Black Hawk Acquisition Corporation has filed an amendment to its 2025 annual report, primarily to include its adopted Compensation Recovery (Clawback) Policy.

Black Hawk Acquisition Corporation reported its fiscal year 2025 results, revealing a definitive business combination agreement with Vesicor Therapeutics, Inc. but also significant going concern uncertainties and internal control weaknesses.

Black Hawk Acquisition Corporation files an amendment to its annual report on Form 10-K to include the Executive Compensation Recovery Policy (Clawback Policy) that was inadvertently omitted in the original filing.

Black Hawk Acquisition Corporation's Form 10-K reveals a net income of $1,915,703 for fiscal year 2024 but raises substantial doubt about its ability to continue as a going concern due to recurring losses and a net capital deficiency.

Black Hawk Acquisition Corp. will merge with Vesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics, valuing Vesicor at $70 million.

Black Hawk Management LLC converted 1,725,000 Class B ordinary shares of Black Hawk Acquisition Corp into an equal number of Class A ordinary shares on April 4, 2024.

Black Hawk Acquisition Corporation is seeking shareholder approval to extend the deadline for completing its initial business combination from June 22, 2025, to December 22, 2026, requiring monthly deposits into its trust account.

Black Hawk Acquisition Corporation has filed a supplement to its definitive proxy statement, seeking shareholder approval to extend its business combination deadline to December 22, 2026, and modifying the terms of its Trust Agreement Amendment Proposal.

Black Hawk Acquisition Corporation has filed a supplement to its proxy statement, seeking shareholder approval to extend its business combination deadline to December 22, 2026, while committing to waive certain dissolution expenses, provide transparency on trust account contributions, and maintain extension terms.

Black Hawk Acquisition Corporation is seeking shareholder approval to extend its business combination deadline by 18 months to December 22, 2026, to facilitate the completion of its proposed merger with Vesicor Therapeutics, Inc.

Black Hawk Acquisition Corporation, a SPAC, is calling an Extraordinary General Meeting on June 20, 2025, to seek shareholder approval for an 18-month extension to its business combination deadline, aiming to complete its merger with Vesicor Therapeutics or find an alternative target.

Black Hawk Acquisition Corporation files an amendment to its S-1 registration statement to register an additional 1,035,000 units for potential sale to the public.

Black Hawk Acquisition Corporation files an amendment to its S-1 registration statement, primarily consisting of exhibits and updated consents.

Black Hawk Acquisition Corporation, a blank check company, files an amendment to its S-1 registration statement for a $60 million initial public offering.

Black Hawk Acquisition Corporation, a newly formed blank check company, aims to raise $60 million through an initial public offering to pursue a merger, share exchange, asset acquisition, or similar business combination with a global target.

First Trust Merger Arbitrage Fund and related entities have reported zero beneficial ownership in Black Hawk Acquisition Corp as of September 30, 2025.

Kerry Propper and Antonio Ruiz-Gimenez have jointly disclosed a 5.8% beneficial ownership stake in Black Hawk Acquisition Corporation, totaling 240,999 ordinary shares each.

AQR Capital Management, along with its affiliates, reported a passive beneficial ownership of 3.36% in Black Hawk Acquisition Corp, holding 139,365 ordinary shares.

W. R. Berkley Corporation and its subsidiary Berkley Insurance Company have reported a 7.4% beneficial ownership stake in Black Hawk Acquisition Corporation as of September 30, 2025.

Wolverine Asset Management and affiliated entities have reported a beneficial ownership of 8.64% in Black Hawk Acquisition Corp, totaling 358,888 ordinary shares.

Mizuho Financial Group, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% in Black Hawk Acquisition Corporation's Common Shares.